TP53BP2 polyclonal Antibody | BS7807

TP53BP2 polyclonal Antibody | BS7807 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB 1:500 - 1:2000

Background: The p53 binding proteins 53BP1 and 53BP2 (Bbp) bind to the central DNA-binding domain of wild type p53, but do not bind mutant p53. The central DNA-binding domain of p53 is required for site-specific DNA binding and is frequently mutated in malignant tumors. Binding of 53BP1 to the L3 loop of p53 and of 53BP2 to the L2 loop of p53 confirms that the loop is dependent on p53 conformation. Site-specific binding also suggests that 53BP1 and 53BP2 are involved in p53-mediated tumor suppression. 53BP1 was isolated from H258 cells and is expressed in Jurkat cells in both the cytoplasm and the nucleus. The N-terminus of 53BP2 is localized to the cytoplasm, while the C-terminus might be localized in the nucleus. 53BP1 promotes cell proliferation by binding to p202, whereas 53BP2 induces cell death by binding to Bcl2 and NFkB p65.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: TP53BP2 polyclonal Antibody detects endogenous levels of TP53BP2 protein.

Molecular Weight: ~ 170 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: 53BP2; Apoptosis stimulating of p53 protein 2; Apoptosis stimulating protein of p53 2; Apoptosis-stimulating of p53 protein 2; ASPP2; ASPP2_HUMAN; Bbp; Bcl2 binding protein; Bcl2-binding protein; NY REN 51 antigen; NY-REN-51 antigen; p53 binding protein 2; p53-binding protein 2; p53BP2; PPP1R13A; Renal carcinoma antigen NY-REN-51; TP53BP2; Tumor protein p53 binding protein 2; Tumor suppressor p53 binding protein 2; Tumor suppressor p53-binding protein 2;

Immunogen: Recombinant full length Human TP53BP2.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Tumor Angiogenesis,